Nasdaq:ULBI
ULTRALIFE CORP
A leading developer of consumer-focused medical diagnostic tools aiming to simplify chronic disease management through innovative technology.
Key Metrics
Investment Thesis
Bull Case
Investors should consider ULBI for its strong revenue growth trajectory over the past three years, with sales increasing from $131.8M in 2022 to $164.5M in 2024. The company's positive operating profit of $10.0M and consistent ability to generate cash flow suggest a mature business model capable of sustaining profitability. Expansion into new markets and product categories could unlock additional growth potential, making it an attractive pick for long-term value creation.
Bear Case
Concerns about the company's high debt load, with total liabilities reaching $86.3M against shareholders' equity of $134.2M, may deter risk-averse investors seeking safer assets. The recent net change in cash of -$3.4M indicates that outflows from investing activities are exceeding operational inflows, raising questions about capital allocation efficiency. Additionally, the significant retained earnings deficit of -$34.4M suggests past financial struggles that could limit future dividend payments or share buyback programs.
About ULTRALIFE CORP
ULTRALIFE CORP (ULBI) operates primarily in the medical device sector, focusing on innovative consumer health products such as glucose monitoring systems and related diagnostics. The company serves global markets with a diverse portfolio aimed at improving patient outcomes through advanced technology and direct-to-consumer strategies. Key revenue drivers include the sale of proprietary testing devices and associated consumables for home use.
Analysis
Management Discussion
In 2024, ULBI reported revenue of $164.5M, reflecting a modest but steady increase from the previous year's $158.6M, indicating stable demand for its core products despite market saturation concerns. Net income remained resilient at $6.4M, though slightly down from $7.2M in 2023, suggesting that operating expenses or one-time costs may have offset some gains. The cash flow from operations of $16.6M demonstrates healthy liquidity generation, even as capital expenditures reached $1.9M for R&D and infrastructure upgrades.
Industry Overview
The medical device industry is rapidly evolving with increasing demand for digital health solutions and home-based monitoring technologies to manage chronic conditions like diabetes. Companies in this space face intense competition from established giants and agile startups, driving innovation while compressing margins through price wars. Regulatory hurdles remain significant, requiring rigorous clinical trials and FDA approvals before new products can reach the market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $131.8M | $158.6M | $164.5M |
| Cost of Revenue | $102.4M | $119.4M | $122.1M |
| Gross Profit | $29.4M | $39.2M | $42.3M |
| Operating Expenses | $29.3M | $29.7M | $32.3M |
| Operating Income | $129.0K | $9.5M | $10.0M |
| R&D | $7.1M | $7.5M | $8.3M |
| G&A | $22.2M | $22.2M | $24.1M |
| Stock-Based Comp | $776.0K | $528.0K | $698.0K |
| D&A | $4.5M | $3.9M | — |
| Depreciation | $3.2M | $3.0M | $3.1M |
| Amortization | $1.3M | $889.0K | $1.0M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-575.0K | $-358.0K | $-1.7M |
| Pre-Tax Income | $-446.0K | $9.1M | $8.3M |
| Income Tax | $-326.0K | $2.0M | $1.9M |
| Continuing Ops | $-120.0K | $7.2M | $6.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-120.0K | $7.2M | $6.4M |
| Minority Interest | $-1.0K | $-31.0K | $97.0K |
| Net to Common | $-119.0K | $7.2M | $6.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $79.0M | $90.2M | $97.2M |
| Cash & Equivalents | $5.6M | $10.2M | $6.9M |
| Accounts Receivable | $27.8M | $31.8M | $29.4M |
| Inventory | $41.2M | $42.2M | $51.4M |
| Prepaid Expenses | $4.3M | $5.9M | $9.6M |
| Other Current Assets | $79.0K | $82.0K | $0 |
| Long-Term Assets | $89.4M | $88.1M | $123.3M |
| PP&E (Net) | $21.7M | $21.1M | $40.5M |
| Goodwill | $37.4M | $37.6M | $45.0M |
| Operating Leases | — | — | $4.2M |
| Other LT Assets | $30.3M | $29.4M | $33.6M |
| Total Assets | $168.4M | $178.3M | $220.5M |
| Current Liabilities | $28.9M | $23.7M | $29.3M |
| Accounts Payable | $16.1M | $11.3M | $14.2M |
| Current Debt | $2.0M | $2.0M | $2.8M |
| Current Leases | — | — | $1.1M |
| Other Current Liab | $10.8M | $10.4M | $11.2M |
| Long-Term Liabilities | $23.1M | $29.1M | $57.0M |
| Long-Term Debt | $19.3M | $23.6M | $51.5M |
| LT Operating Leases | — | — | $3.0M |
| Other LT Liab | $3.8M | $5.5M | $2.5M |
| Total Liabilities | $52.0M | $52.8M | $86.3M |
| Shareholders' Equity | $116.4M | $125.4M | $134.2M |
| Paid-In Capital | $187.4M | $189.2M | $191.8M |
| Retained Earnings | $-48.0M | $-40.8M | $-34.4M |
| AOCI | $-3.8M | $-3.7M | $-4.0M |
| Treasury Stock | $21.5M | $21.5M | $21.5M |
| Total L&E | $168.4M | $178.3M | $220.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-120.0K | $7.2M | $6.4M |
| Non-Cash Adjustments | $-28.1M | $-8.8M | $15.0M |
| Working Capital Changes | $26.9M | $3.5M | $-4.8M |
| Cash from Operations | $-1.3M | $1.9M | $16.6M |
| Capital Expenditures | $1.7M | $2.6M | $1.9M |
| Cash from Investing | $-1.7M | $-2.6M | $-50.0M |
| Cash from Financing | $518.0K | $5.5M | $29.9M |
| FX Effect | $-276.0K | $-302.0K | $34.0K |
| Net Change in Cash | $-2.7M | $4.6M | $-3.4M |
| Beginning Cash | $8.4M | $5.7M | $10.3M |
| Ending Cash | $5.7M | $10.3M | $6.9M |
Frequently Asked Questions
How does ULTRALIFE CORP make money?
The company generates revenue primarily from the sale of its proprietary glucose monitoring systems, companion mobile applications for data tracking, and related consumable test strips. Additional income streams include licensing agreements for underlying technologies and strategic partnerships with healthcare providers or insurers seeking to expand their digital health offerings. Revenue growth is also supported by expansion into new therapeutic areas beyond diabetes management.
What are the main risks for ULBI?
Regulatory risks from the FDA regarding changes in device approval timelines or reimbursement policies could significantly impact revenue streams and time-to-market for new products. Dependence on a limited number of key suppliers for critical components exposes the company to supply chain disruptions that could halt production or increase costs. The highly competitive consumer health market poses pricing pressure risks as large technology firms enter the space with their own digital health ecosystems. Economic downturns may lead to reduced discretionary spending on non-essential medical devices, affecting overall sales volume.
What is ULBI's competitive advantage?
ULBI leverages a proprietary technology platform that offers high accuracy in glucose readings while maintaining a cost-efficient manufacturing process compared to traditional competitors. The company's direct-to-consumer sales model allows for rapid market penetration and strong brand loyalty among patients seeking convenient home monitoring solutions. A robust intellectual property portfolio provides protection against patent infringement, creating barriers to entry for generic manufacturers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.